Newsroom | 30890 results

NASHVILLE, Tenn.--(BUSINESS WIRE)--Aegis Sciences Corporation (“Aegis” or the “Company”) today announced it has named Joel Galanter Interim CEO, replacing Frank Basile who served as the company’s CEO since 2017. With more than a decade in senior executive leadership at Aegis, Galanter brings deep institutional knowledge and broad experience across the Company's operations, regulatory environment, and strategic priorities. Galanter has directly overseen the Company's legal, regulatory, governmen...

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ) clarifies its announcement that it has been awarded a $28 million contract extension, with an additional option of $30 million through the Defense Advanced Research Projects Agency (DARPA) It’s About Time program. Under the program, IonQ will advance its scalable clock production capabilities for its Evergreen-05 optical atomic clocks and deliver 125 units to U.S. government customers. The clocks are designed for mission-critical application...

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. “We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our f...

DUBLIN--(BUSINESS WIRE)--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights....

PALO ALTO, Calif.--(BUSINESS WIRE)--TCGX Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of 8,625,000 Class A ordinary shares at a price of $10.00 per share, including the 1,125,000 shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The Class A ordinary shares are listed on The Nasdaq Capital Market (“Nasdaq”) and began trading under the ticker symbol “TCGX” as of August 5, 2026. The Company is a special purp...

COLUMBUS, Ohio--(BUSINESS WIRE)--Battelle recently welcomed members of the National Security Commission on Emerging Biotechnology (NSCEB) to its Columbus headquarters as part of the NSCEB’s national roadshow providing an inside look at biotechnology research, biosecurity capabilities and partnerships advancing U.S. competitiveness, supply chain resilience and national security. The visit brought together Commission members, congressional staff, biotechnology leaders, government partners, academ...

ST. PAUL, Minn.--(BUSINESS WIRE)--The board of directors of Ecolab Inc. today declared a regular quarterly cash dividend of $0.73 per common share, to be paid October 15, 2026, to shareholders of record at the close of business on September 15, 2026. Ecolab has paid cash dividends on its common stock for 89 consecutive years. About Ecolab A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global leader in water, hygiene and infection prevention solutions and services that prote...

TULSA, Okla.--(BUSINESS WIRE)--Four startups headquartered in Colorado, Florida and Texas have been selected as winners of the 2026 Rose Rock Bridge Showcase. Austere Environmental, BiaTech, BigMachine AI and Intellicess will receive a share of $400,000 in non-dilutive funding and establish a presence in Tulsa to pilot and advance their technologies over the next year. The winning startups were selected from a pool of 85 highly qualified applicants. Collectively, they have already raised over $...

HERNDON, Va.--(BUSINESS WIRE)--Indigo IT today announced it has been awarded a position on NASA's Solutions for Enterprise-Wide Procurement (SEWP) VI Government-Wide Acquisition Contract (GWAC) Category B Enterprise IT services, a Best-in-Class, multi-award vehicle that gives federal agencies a streamlined path to acquire innovative information technology products and services. The award adds SEWP VI to Indigo IT's existing portfolio of federal contract vehicles and positions the company to com...

HOUSTON--(BUSINESS WIRE)--IPS HEART, Inc., a biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cell replacement therapies, announced that the FDA has granted Rare Pediatric Drug Designation for ISX9-CPC, for the treatment of cardiomyopathies associated with dystrophinopathies. Redefining the Therapeutic Paradigm: Generating New Human Muscle Duchenne muscular dystrophy (DMD) leads to progressive skeletal muscle loss, severe cardiac fibrosis, and premature death fr...